Research & Publications > Clinical
Research > Cardiovascular
Disease Prevention Center > Cardiovascular
Disease Prevention Center
(Continued)
A 16-Week Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of Hypolipidemic Therapy with an HMGCOA Reductase Inhibitor (Atorvastatin) in Type 2 Diabetes Mellitus Patients Treated with Rosiglitazone (BRL49653) 4 mg Bid
Sponsor: SmithKline Beecham
Dates: 4/99 - 3/00
Principal Investigator: David Capuzzi, MD
A Double-Blind Comparison of 10, 20, 40 and 80 mg Doses of a Modified-Release Formulation of Pravastatin, of Atorvastatin 10 mg and of Simvastatin with Placebo in Hypercholesterolemic Subjects
Sponsor: Bristol-Myers Squibb
Dates: 8/99 - 7/00
Principal Investigator: David Capuzzi, MD
A 24-Week, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety of ZD4522 and NIASPAN Monotherapy. As well as Selected Combinations of ZD4522 and NIASPAN in the Treatment of Subjects with Type IIb or IV Hyperlipidemia
Study: AD4522IL/0029
Sponsor: AstraZeneca
Dates: 10/99 - 7/00
Principal Investigator: David Capuzzi, MD
Efficacy, Dose-Ranging and Safety for REJ-241947 in Type 2 Diabetic Subjects Inadequately Controlled on Diet, Metformin of Sulfonylurea: A 24-Week Double-Blind, Randomized, Placebo-Controlled Study
Protocol: PRI/947-INT-4
Sponsor: The R.W. Johnson Pharmaceutical Research Institute
Dates: 6/00 - 8/01
Principal Investigator: David Capuzzi, MD
A 28-Week, Double-Blind, Observer-Blind-to-Lipid Values, Active-Controlled, Randomized, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of Fluvastatin Slow Release Form (80 mg) Administered Once Daily in the Evening in Subjects with Primary Hypercholesterolemia Compared to Lescol (40 mg)
Sponsor: Novartis Pharmaceuticals Corp.
Dates: 1/98 - 5/00
Principal Investigator: John Morgan, MD
< Back
More >
|
|
